NEW YORK (GenomeWeb News) – Meridian Bioscience today said that its fiscal fourth-quarter sales rose 6 percent year over year with its molecular diagnostic business contributing to the growth.

For the three months ended Sept. 30, the company posted $43.7 million in revenues, compared to $41.3 million a year ago, beating the consensus analyst estimate of $43.0 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.